

Session 1

Understanding the implications of germline testing in a community practice

08:30 - 10:40

08:30 - 09:00

Keynote lecture: How germline mutations have impacted clinic practice: PARP inhibitors as targeted therapy for personalized medicine

Speaker: TBA

09:00 - 09:20

Testing germline mutations: how much is enough?

Speaker: TBA

09:20 - 09:40

How should germline mutations be tested: Is methodology important?

Speaker: TBA

09:40 - 10:00

Counselling patients with BRCA mutations: how much is enough?

Speaker: TBA

10:00 - 10:20

Molecular genetics and pathology of inherited breast and ovarian tumors: what a clinician needs to know

Speaker: TBA

10:20 - 10:40

Screening and prevention of cancer in healthy individuals with germline mutations: A practical approach

Speaker: TBA

10:40 - 11:00

MORNING COFFEE BREAK

Session 2

Implications of variance of unknown significance: large volume of diminishing returns?

11:00 - 13:00

11:00 - 11:30

What does a VUS mean and does it matter?

Speaker: TBA

11:30 - 12:00

Risk assessment for carriers of BRCA variants of uncertain significance (VUS)

Speaker: TBA

12:00 - 12:30

How can large data sets reduce the incidence of VUS?

Speaker: TBA

12:30 - 13:00

Panel discussion: Dealing with implications of germline mutations in the community

Moderator:

Panelist:

13:00 - 14:00

LUNCH BREAK

Session 3

Managing patients with BRCA mutations in breast cancer and beyond

14:00 - 16:00

14:00 - 14:30

Integrating BRCA mutations into the management of Gynecological malignancies
Speaker: Robert Coleman

14:30 - 15:00

Integrating PARP inhibitors into the management of breast cancer: where are we?
Speaker: TBA

15:00 - 15:30

BRCA mutations as an emerging biomarker in GI malignancies
Speaker: TBA

15:30 - 16:00

Germline mutations and GU malignancies: Is it time to change treatment algorithms?
Speaker: TBA

16:00 - 16:15

MORNING COFFEE BREAK

Session 4

A global look at BRCA mutations

16:15 - 18:00

16:15 - 16:30

A snapshot view from the Middle East
Speaker: TBA

16:30 - 16:45

A snapshot view from Malaysia
Speaker: TBA

16:45 - 17:00

A snapshot view from India
Speaker: TBA

17:00 - 17:15

A snapshot view from HongKong
Speaker: TBA

17:15 - 17:30

A snapshot view from Singapore
Speaker: Joanne Ngeow

17:30 - 17:45

Building a teleogenetic platform for the community
Speaker: Aparna Dhar

17:45 - 18:15

Panel discussion: Challenging cases of Cancer with BRCA mutations
Moderator:
Panelist:

Session 5

Integrating germline and somatic mutations: Taking precision medicine forward

08:30 - 11:00

08:30 - 09:00

Keynote lecture:

Precision oncology in 2019: integrating germline and somatic mutations

Speaker: TBA

09:00 - 09:20

Sequencing tumors: understanding the implications in the oncology community

Speaker: TBA

09:20 - 09:40

Understanding somatic BRCA mutations: how will it impact practice?

Speaker: TBA

09:40 - 10:00

Whole genome or whole exome sequencing:
choosing the right test for the right patient

Speaker: TBA

10:00 - 10:20

A clinician's guide to navigating through a molecular profiling report

Speaker: TBA

10:20 - 10:40

The upcoming role of artificial intelligence and its implications on the practicing oncologist

Speaker: TBA

10:40 - 11:00

Molecular tumor board discussion:

Challenging cases using germline and somatic mutation testing

Moderator:

Panelist: